Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Login and Edit functionaility are currrently unavailable.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML.

Ibrutinib selectively targets FLT3-ITD in mutant FLT3-positive AML. Leukemia. 2016 Mar; 30(3):754-7.

View in: PubMed

© 2022 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.